SCHEMBL1542476

SCHEMBL1542476

COc1c(NC(=O)c2ccc(N)cc2F)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.44
CD274 Q9NZQ7 2/20 0.43
BTK Q06187 3/20 0.41
NTRK1 P04629 1/20 0.36
SCN8A Q9UQD0 3/20 0.35
SCN10A Q9Y5Y9 3/20 0.35
ABL1 P00519 1/20 0.35
CFTR P13569 1/20 0.35
HDAC1 Q13547 1/20 0.34
TP53 P04637 1/20 0.34
ABCB1 P08183 1/20 0.33
ABCC1 P33527 1/20 0.33
LCLAT1 Q6UWP7 1/20 0.33
ACLY P53396 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542564 0.90 CYP3A4 (0.43) CYP3A4CD274BTKSCN8ASCN10A
SCHEMBL1543054 0.90 CYP3A4 (0.44) CYP3A4CD274BTKNTRK1SCN8A
SCHEMBL2127468 0.90 CYP3A4 (0.44) CYP3A4CD274ACLYKDM4EALDH1A1
SCHEMBL1542748 0.86 CYP3A4 (0.47) CYP3A4CD274BTKABL1HDAC1
SCHEMBL2127612 0.86 CYP3A4 (0.58) CYP3A4CD274BTKSCN8ASCN10A
SCHEMBL1543460 0.84 CYP3A4 (0.44) CYP3A4CD274BTKABL1HDAC1
SCHEMBL1542928 0.83 CYP3A4 (0.44) CYP3A4CD274BTKABL1KDM4E
SCHEMBL1542657 0.81 CYP3A4 (0.49) CYP3A4BTKABL1TP53ABCB1
SCHEMBL1542627 0.80 CYP3A4 (0.44) CYP3A4CD274BTKABL1HDAC1
SCHEMBL1542931 0.79 CYP3A4 (0.44) CYP3A4CD274BTKABL1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885CD274 3357/4885BTK 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.